Shield Therapeutics (LON:STX) Shares Up 13% - What's Next?

Key Points

• Shield Therapeutics' shares surged 13% on Wednesday, reaching a high of GBX 5.30 before closing at GBX 5.20, with trading volume increasing by 165% compared to the average.
• The company has a market capitalization of £51.32 million and a notably high debt-to-equity ratio of 3,691.50, indicating significant leverage.
• Shield Therapeutics is focused on addressing iron deficiency with its product Accrufer®/Feraccru®, which has been launched in the U.S. to meet a substantial medical need.

Shield Therapeutics plc (LON:STX - ) shot up 13% on Wednesday . The company traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.20 ($0.07). 5,593,089 shares changed hands during mid-day trading, an increase of 165% from the average session volume of 2,108,223 shares. The stock had previously closed at GBX 4.60 ($0.06).

Shield Therapeutics Stock Performance

The company has a market capitalization of £51.32 million, a P/E ratio of -1.34 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock's 50 day simple moving average is GBX 3.43 and its two-hundred day simple moving average is GBX 3.06.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.